Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

by Audrey Coilly, Jérôme Dumortier, Danielle Botta-Fridlund, Marianne Latournerie, Vincent Leroy, Georges-Philippe Pageaux, Hélène Agostini, Emiliano Giostra, Christophe Moreno, Bruno Roche, Teresa Maria Antonini, Olivier Guillaud, Pascal Lebray, Sylvie Radenne, Anne-Catherine Saouli, Yvon Calmus, Laurent Alric, Maryline Debette-Gratien, Victor De Ledinghen, François Durand, Christophe Duvoux, Didier Samuel, Jean-Charles Duclos-Vallée Background and aims First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype 1 infection in most countries for 3 years. We have investigated the efficacy and tolerance of this triple therapy in transplanted patients experiencing a recurrence of HCV infection on the liver graft. Patients This cohort study enrolled 81 liver transplant patients (Male: 76%, mean age: 55.8±9.7 years) with severe HCV recurrence (F3 or F4: n = 34 (42%), treatment experienced: n = 44 (54%)), treated with boceprevir (n = 36; 44%) or telaprevir (n = 45; 56%). We assessed the percentages of patients with sustained virological responses 24 weeks after therapy (SVR24), and safety. Results The SVR24 rate was 47% (telaprevir: 42%; boceprevir: 53%, P = ns). At baseline, a normal bilirubin level (p = 0.0145) and albumin level >35g/L (p = 0.0372) and an initial RBV dosage of ≥800 mg/day (p = 0.0033) predicted SVR24. During treatment, achieving an early virological...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research